Clinical outcome and pattern of recurrence in patients with triple negative breast cancer as compared with non-triple negative breast cancer group

Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India

“…In world cancer report 2008, [9] South East Asia region SEAO in which India comprises of 67% of total population of the region, it was estimated that there were 1,589,000 incident cases of cancer in year 2008 (758,000 in men and 831,000 in women) and 1,072,000 deaths from cancer (approximately 557,000 in men and 515,000 in women). The overall rate of TNBC in our study (34.4%) is comparable to results obtained by Saha et al [6] (30.4%) and Keam et al [10] (32.4%), however our results are higher as compared to studies by Ambroise et al (25%), [11] Krishnamurthy et al (18.5%), [4] Tan et al (17.6%), [12] Li et al (12.1%), [8] Bauer et al (12.5%), [13] Dent et al (11.2%). [14] In our study, the mean age at diagnosis was significantly younger in TNBC patients (47.4 years) as compared to non-TNBC group (52 years) (P = 0.014).…”

“…[14] In our study, the mean age at diagnosis was significantly younger in TNBC patients (47.4 years) as compared to non-TNBC group (52 years) (P = 0.014). Similar results were seen by Saha et al [6] in a study involving 1026 patients of which 312 patients represented TNBC. Mean age at diagnosis in TNBC was 48.8 years as compared to 53.6 years in non-TNBC (P < 0.002).…”

“…[4] Triple negative cancers are characterized by lack of expression of ER, PR, and HER-2 neu. [6] These cancers occur in approximately 10-25% of all breast carcinomas. [4] Triple negative breast cancers (TNBCs) are clinically characterized as more aggressive and less responsive to standard treatment and are associated with poor overall patient prognosis.…”

Exploring specific prognostic biomarkers in triple-negative breast cancer

“…Unfortunately, due to the devoid of early detection biomarkers and clear therapeutic targets, TNBC patients are often diagnosed late with a high histological grade, and do not benefit from hormonal or targeted therapies 6 . As a result, patients with TNBC usually suffer high risks of metastasis and distal recurrence, and have poor prognosis with shortened disease-free survival (DFS) and overall survival (OS) 7,8 . Hence, as a serious clinical challenge, TNBC calls for urgent needs of developing novel prognostic biomarkers and therapeutic targets.…”

Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different?

“…At a median follow-up of 58 months, the recurrence occurred in 16% cases with the lung being the most common site followed by the brain [28,29]. e rarity of local recurrence and high rates of distant recurrence in our study suggest that TNBC has a propensity to develop visceral metastasis during the course of disease [30,31]. At 6.5 years, the DFS of BL and NBL group was 62% and 78%, respectively, without any significant difference.…”